1. Home
  2. EXAS vs GL Comparison

EXAS vs GL Comparison

Compare EXAS & GL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • EXAS
  • GL
  • Stock Information
  • Founded
  • EXAS 1995
  • GL 1900
  • Country
  • EXAS United States
  • GL United States
  • Employees
  • EXAS N/A
  • GL N/A
  • Industry
  • EXAS Medical Specialities
  • GL Life Insurance
  • Sector
  • EXAS Health Care
  • GL Finance
  • Exchange
  • EXAS Nasdaq
  • GL Nasdaq
  • Market Cap
  • EXAS 9.1B
  • GL 9.9B
  • IPO Year
  • EXAS N/A
  • GL N/A
  • Fundamental
  • Price
  • EXAS $45.60
  • GL $135.45
  • Analyst Decision
  • EXAS Strong Buy
  • GL Buy
  • Analyst Count
  • EXAS 22
  • GL 12
  • Target Price
  • EXAS $66.43
  • GL $151.00
  • AVG Volume (30 Days)
  • EXAS 3.9M
  • GL 820.0K
  • Earning Date
  • EXAS 08-06-2025
  • GL 07-23-2025
  • Dividend Yield
  • EXAS N/A
  • GL 0.80%
  • EPS Growth
  • EXAS N/A
  • GL 13.31
  • EPS
  • EXAS N/A
  • GL 12.54
  • Revenue
  • EXAS $2,939,949,000.00
  • GL $5,883,393,000.00
  • Revenue This Year
  • EXAS $14.61
  • GL $7.77
  • Revenue Next Year
  • EXAS $12.71
  • GL $5.22
  • P/E Ratio
  • EXAS N/A
  • GL $10.80
  • Revenue Growth
  • EXAS 12.55
  • GL 4.02
  • 52 Week Low
  • EXAS $38.81
  • GL $95.09
  • 52 Week High
  • EXAS $72.83
  • GL $144.00
  • Technical
  • Relative Strength Index (RSI)
  • EXAS 44.47
  • GL 53.68
  • Support Level
  • EXAS $40.55
  • GL $138.96
  • Resistance Level
  • EXAS $45.45
  • GL $142.21
  • Average True Range (ATR)
  • EXAS 2.04
  • GL 3.13
  • MACD
  • EXAS 0.07
  • GL -0.66
  • Stochastic Oscillator
  • EXAS 63.10
  • GL 4.74

About EXAS Exact Sciences Corporation

Exact Sciences, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test is a noninvasive stool-based DNA test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It is also developing liquid biopsy tests for molecular residual disease, colorectal cancer screening, and multicancer screening.

About GL Globe Life Inc.

Globe Life Inc is an insurance holding company. It provides a variety of life and supplemental health insurance products and annuities to a broad base of customers. The company's core operations are organized into three reportable segments: life insurance, supplemental health insurance and investments. Investment activities, conducted by the investment segment, focus on seeking investments with a yield and term appropriate to support the insurance product obligations. These investments generally consist of fixed maturities and, over the long term, the expected yields are considered when setting insurance premium rates and product profitability expectations.

Share on Social Networks: